Company Analysis
Sign in

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Nasdaq: BBOT · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2023
Full chart Alerts Compare
Grade4.8
◀ Past 3.6● Present 4.2▶ Future 6.1
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Who owns BridgeBio Oncology Therapeutics, Inc.

As filed with the SEC
Holders of 5% or more
7
Bihua Chen holds 22.6% of Common Stock, as its SCHEDULE 13D/A filed Aug 13, 2025 says.
Directors and officers
19
report now, of 20 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Bihua Chen
SCHEDULE 13D/A · filed Aug 13, 2025 · Common Stock · 31.6% in Mar 4, 2025
22.6%
Bihua Chen
SCHEDULE 13D/A · filed Jul 6, 2026 · Common Stock
22.3%
BridgeBio Pharma LLC
SCHEDULE 13D · filed Aug 18, 2025 · Common Stock, $0.0001 par value
17.5%
BlackRock Portfolio Management LLC
SCHEDULE 13G · filed Apr 15, 2025 · Common Stock
7.9%
Deerfield Management Company, L.P.
SCHEDULE 13G · filed Aug 18, 2025 · Common Stock
6.17%
BC Global Opportunities IX LP
SCHEDULE 13G · filed Sep 3, 2025 · Common Stock
5.5%
Sculptor Capital LP
SCHEDULE 13G · filed Jul 24, 2025 · Class A Ordinary Shares, par value $0.0001 per share
5.12%
Millennium Management LLC
SCHEDULE 13G/A · filed Jul 30, 2025 · Class A Ordinary Shares, par value $0.0001 per share · reported falling below 5%
under 5%
Citadel Advisors LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Class A ordinary share, par value $0.0001 per share (the "Shares") · reported falling below 5%
under 5%
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
under 5%
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 22, 2025 · Class A Stock · reported falling below 5%
under 5%
What BBOT reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
BridgeBio Pharma
An entity · legal entity · owns, named in the 10-K filed Mar 5, 2026
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 23, 2025 to Oct 23, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
24
2024 runs to Oct 23, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.
SI Assistanton BBOT · research, not advice